AMENDMENTS TO THE CLAIMS

1. (Currently amended) An adjuvant comprising a cationic surfactant and ~~the~~ an antigenic component comprising an apolar fraction or part of the apolar fraction of ~~the~~ a total lipid extract of a mycobacterium~~, e.g. the BCG, *M. microti, M. tuberculosis* and *M. vaccae*~~.

2. (Currently amended) An adjuvant according to claim 1 ~~where~~ , wherein the part of the apolar fraction of the lipid extract ~~can be~~ is selected from the group consisting of phthiocerol dimycocerosates, trehalose mycolipenates, glycosylated phenol phthiocerols ~~(including phenolic glycolipids, PGL's)~~, thehalose mycolates, sulfolipids, triacylglycerols ~~or~~ and menaquinones.

3. (Canceled)

4. (Currently amended) An adjuvant according to claim ~~3~~ 1, wherein ~~where~~ the surfactant is DDA, DODA, DC-chol or DOTAP.

5. (Canceled)

6. (Currently amended) A vaccine comprising an adjuvant according to claim ~~1-5~~ 1.

7. (Currently amended) A vaccine according to claim 6 for ~~parenterally~~ parenteral, oral or mucosal administration.

8. (Currently amended) A vaccine according to claim ~~7~~ 6, wherein ~~where~~ the antigenic component comprises an antigenic epitope from a virulent mycobacterium~~, e.g. *Mycobacterium tuberculosis, M. bovis* or *M. africanum*~~.

9. (Currently amended) A vaccine according to claim 8 ~~where~~ , wherein the antigenic component ~~is~~ comprises an ESAT6-Ag85B hybrid or a fragment thereof.

10. (Currently amended) ~~A~~ An improved vaccine ~~according to claim 7~~ for ~~treating~~ cancer, allergy or an autoimmune ~~diseases~~ disease, wherein the improvement comprises the adjuvant of claim 1.

11. (Currently amended) A delivery system comprising an adjuvant according to Claim ~~1-5~~ 1.

12. (Currently amended) ~~Preparing~~ A method of preparing an adjuvant according to ~~claim 1-5~~ claim 1 ~~using thin lipid film method~~ comprising:

dissolving a cationic surfactant and an antigenic component that comprises an apolar fraction or part of the apolar fraction of a total lipid extract of a mycobacterium in a solvent;

evaporating said solvent from said dissolved cationic surfactant and antigenic component with a gas;

drying said cationic surfactant and said antigenic component;

bringing said cationic surfactant and said antigenic component into a solution so as to form a thin lipid film; and

formulating the adjuvant of claim 1 from said thin lipid film.

13. (New) The adjuvant of claim 1, wherein said mycobacterium is BCG, *M. microti*, *M. tuberculosis* or *M. vaccae*.

14. (New) The adjuvant of claim 2, wherein said glycosylated phenol phthiocerols are phenolic glycolipids.

15. (New) The vaccine of claim 8, wherein said virulent bacterium is selected from the group consisting of *M. tuberculosis*, *M. bovis* and *M. africanum*.

16. (New) An adjuvant comprising a neutral or anionic surfactant and an antigenic component comprising an apolar fraction or part of the apolar fraction of a total lipid extract of a mycobacterium.

17. (New) An adjuvant according to claim 16 wherein the surfactant is DOPE/PC or DOPE/PC/PG.